Literature DB >> 29340909

Liposomal Amphotericin B as Monotherapy in Relapsed Coccidioidal Meningitis.

Ethan R Stewart1, Matthew L Eldridge1, Ian McHardy2, Stuart H Cohen1, George R Thompson3,4.   

Abstract

Coccidioidal meningitis remains a difficult clinical problem, and despite life-long therapy with triazole antifungals, relapses of disease and medication intolerance occur necessitating salvage treatment. We report two patients with recurrent coccidioidal meningitis who improved following a 2-week course of liposomal amphotericin B monotherapy and discuss potential advantages of this treatment option.

Entities:  

Keywords:  Coccidioides; Coccidioidomycosis; Liposomal amphotericin B; Meningitis; Relapse

Mesh：

Substances：

Year:  2018        PMID： 29340909     DOI： 10.1007/s11046-017-0240-7

Source DB:  PubMed          Journal:  Mycopathologia        ISSN： 0301-486X            Impact factor:   2.574


  13 in total

Review 1.  Pulmonary coccidioidomycosis.

Authors:  George R Thompson
Journal:  Semin Respir Crit Care Med       Date:  2011-12-13       Impact factor: 3.119

2.  Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.

Authors:  Richard J Hamill; Jack D Sobel; Wafaa El-Sadr; Philip C Johnson; John R Graybill; Kedarnath Javaly; David E Barker
Journal:  Clin Infect Dis       Date:  2010-07-15       Impact factor: 9.079

Review 3.  Lipid formulations of amphotericin B: recent progress and future directions.

Authors:  J W Hiemenz; T J Walsh
Journal:  Clin Infect Dis       Date:  1996-05       Impact factor: 9.079

4.  2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis.

Authors:  John N Galgiani; Neil M Ampel; Janis E Blair; Antonino Catanzaro; Francesca Geertsma; Susan E Hoover; Royce H Johnson; Shimon Kusne; Jeffrey Lisse; Joel D MacDonald; Shari L Meyerson; Patricia B Raksin; John Siever; David A Stevens; Rebecca Sunenshine; Nicholas Theodore
Journal:  Clin Infect Dis       Date:  2016-07-27       Impact factor: 9.079

Review 5.  Intrathecal amphotericin in the management of coccidioidal meningitis.

Authors:  D A Stevens; S A Shatsky
Journal:  Semin Respir Infect       Date:  2001-12

6.  Liposomal amphotericin B therapy of murine histoplasmosis.

Authors:  J R Graybill; R Bocanegra
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

7.  Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group.

Authors:  J N Galgiani; A Catanzaro; G A Cloud; R H Johnson; P L Williams; L F Mirels; F Nassar; J E Lutz; D A Stevens; P K Sharkey; V R Singh; R A Larsen; K L Delgado; C Flanigan; M G Rinaldi
Journal:  Ann Intern Med       Date:  2000-11-07       Impact factor: 25.391

8.  In vitro interactions between amphotericin B and hydrocortisone: potential implications for intrathecal therapy.

Authors:  Greg Hodge; Stuart H Cohen; George R Thompson
Journal:  Med Mycol       Date:  2015-07-10       Impact factor: 4.076

9.  Posaconazole therapy for chronic refractory coccidioidomycosis.

Authors:  David A Stevens; Adrian Rendon; Veronica Gaona-Flores; Antonino Catanzaro; Gregory M Anstead; Lisa Pedicone; J Richard Graybill
Journal:  Chest       Date:  2007-06-15       Impact factor: 9.410

10.  Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS.

Authors:  Philip C Johnson; L Joseph Wheat; Gretchen A Cloud; Mitchell Goldman; Dan Lancaster; David M Bamberger; William G Powderly; Richard Hafner; Carol A Kauffman; William E Dismukes
Journal:  Ann Intern Med       Date:  2002-07-16       Impact factor: 25.391
View more
  4 in total

1.  Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis.

Authors:  Ritam Sidhu; David B Lash; Arash Heidari; Piruthiviraj Natarajan; Royce H Johnson
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

Review 2.  Nanovehicles in the improved treatment of infections due to brain-eating amoebae.

Authors:  Mohammad Ridwane Mungroo; Naveed Ahmed Khan; Ayaz Anwar; Ruqaiyyah Siddiqui
Journal:  Int Microbiol       Date:  2021-08-09       Impact factor: 2.479

Review 3.  Progress in the Application of Nanoparticles and Graphene as Drug Carriers and on the Diagnosis of Brain Infections.

Authors:  Mahmood Barani; Mahwash Mukhtar; Abbas Rahdar; Ghasem Sargazi; Anna Thysiadou; George Z Kyzas
Journal:  Molecules       Date:  2021-01-02       Impact factor: 4.411

Review 4.  Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections.

Authors:  Brenda Kischkel; Suélen A Rossi; Samuel R Santos; Joshua D Nosanchuk; Luiz R Travassos; Carlos P Taborda
Journal:  Front Cell Infect Microbiol       Date:  2020-09-03       Impact factor: 5.293
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.